AlphaStocks

AZN vs INFY

ASTRAZENECA PLC vs Infosys Ltd — Side-by-Side Stock Comparison

AZN

ASTRAZENECA PLC

8.4

Strong Buy

$200.99

INFY

Infosys Ltd

0.5

Avoid

$13.31

AZN vs INFY: Which is the Better Investment?

ASTRAZENECA PLC (AZN) scores 8.4/10 while Infosys Ltd (INFY) scores 0.5/10 on AlphaStocks' composite model. ASTRAZENECA PLC has the higher composite rating of Strong Buy. On a P/E basis, Infosys Ltd trades at 17.4x, making it the more attractively priced of the two.

This comparison is algorithmically generated and is not financial advice.

MetricAZNINFY
Scores & Fundamentals
Composite Score8.4/100.5/10
RatingStrong BuyAvoid
Price$200.99$13.31
P/E Ratio30.417.4
ROE21.9%28.9%
Market Cap$312B$55B
Fair Value$192.63
Dividend Yield1.6%4.3%
Sector Rank#3 of 1127#1123 of 1127
Model Verdicts
PiotroskiStrongLimited Data
BuffettStrongLimited Data
GrahamCautionNeutral
LynchNeutralLimited Data
GreenblattNeutralLimited Data
View full AZNanalysis →View full INFYanalysis →
Compare any two stocks →

AZN vs INFY: Which Stock Scores Higher?

ASTRAZENECA PLC (AZN) and Infosys Ltd (INFY) are among the most compared stocks in the S&P 500. AZN currently leads with a composite score of 8.4/10 (Strong Buy) compared to INFY's 0.5/10 (Avoid).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer